{
    "id": "64137616201352f04a000041",
    "question": "Anemia is not associated with chronic kidney failure",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine if anemia is not associated with chronic kidney failure, we need to analyze the relationship between the two conditions. Chronic kidney failure is a condition where the kidneys lose their ability to filter waste and excess fluids from the blood, leading to a buildup of toxins and a decline in the production of erythropoietin (EPO), a hormone that stimulates red blood cell production. Anemia is a condition characterized by a lack of red blood cells or a decrease in the amount of hemoglobin in the blood. The relationship between chronic kidney failure and anemia is well-established, as the kidneys produce EPO, and a decline in kidney function can lead to a decrease in EPO production, resulting in anemia. Therefore, anemia is indeed associated with chronic kidney failure. The correct answer is not A. To determine if anemia is not associated with chronic kidney failure, we can look at the options provided and see that B is the correct answer.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_8003",
            "title": "InternalMed_Harrison",
            "content": "Progressive CKD is usually associated with a moderate to severe hypoproliferative anemia; the level of the anemia corre-EPO Marrow lates with the stage of CKD. Red cells are typically normocytic and normochromic, and reticulocytes are decreased. The anemiaIron is primarily due to a failure of EPO production by the diseased kidney and a reduction in red cell survival. In certain forms of acuteInterferon \u00b0 renal failure, the correlation between the anemia and renal function is weaker. Patients with the hemolytic-uremic syndrome increase erythropoiesis in response to the hemolysis, despite renal failure requiring Rheumatoid arthritis dialysis. Polycystic kidney disease also shows a smaller degree of EPO FIGURE 126-4 Suppression of erythropoiesis by inflammatory deficiency for a given level of renal failure. By contrast, patients with cytokines. Through the release of tumor necrosis factor (TNF) and diabetes or myeloma have more severe EPO deficiency for a given level interferon \u03b3"
        },
        {
            "id": "InternalMed_Harrison_18294",
            "title": "InternalMed_Harrison",
            "content": "Anemia is common in heart failure patients, reduces functional status and quality of life, and is associated with increased proclivity for hospital admissions and mortality. Anemia in heart failure is more common in the elderly, in those with advanced stages of HFrEF, in the presence of renal insufficiency, and in women and African Americans. The mechanisms include iron deficiency, dysregulation of iron metabolism, and occult gastrointestinal bleeding. Intravenous iron using either iron sucrose or carboxymaltose (Ferric Carboxymaltose Assessment in Patients with Iron Deficiency and Chronic Heart Failure [FAIR-HF] trial) has been shown to correct anemia and improve functional capacity. Erythropoiesis-regulating agents such as erythropoietin analogues have been studied with disappointing results. The Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial evaluated 2278 mild-to-moderate anemia patients with HFrEF and demonstrated that treatment with darbepoetin alfa did"
        },
        {
            "id": "InternalMed_Harrison_7953",
            "title": "InternalMed_Harrison",
            "content": "John W. Adamson Anemias associated with normocytic and normochromic red cells and an inappropriately low reticulocyte response (reticulocyte index <2\u20132.5) are hypoproliferative anemias. This category includes early iron deficiency (before hypochromic microcytic red cells develop), acute and chronic inflammation (including many malignancies), renal disease, hypometabolic states such as protein malnutrition and endocrine deficiencies, and anemias from marrow damage. Marrow damage states are discussed in Chap. 130. Hypoproliferative anemias are the most common anemias, and in the clinic, iron deficiency anemia is the most common of these followed by the anemia of inflammation. The anemia of inflammation, similar to iron deficiency, is related in part to abnormal iron metabolism. The anemias associated with renal disease, inflammation, cancer, and hypometabolic states are characterized by a suboptimal erythro poietin response to the anemia."
        },
        {
            "id": "Pharmacology_Katzung_3690",
            "title": "Pharmacology_Katzung",
            "content": "The availability of erythropoiesis-stimulating agents (ESAs) has had a significant positive impact for patients with several types of anemia (Table 33\u20134). The ESAs consistently improve the hematocrit and hemoglobin level, often eliminate the need for transfusions, and reliably improve quality of life indices. The ESAs are used routinely in patients with anemia secondary to chronic kidney disease. In patients treated with an ESA, an increase in reticulocyte count is usually observed in about 10 days and an increase in hematocrit and hemoglobin levels in 2\u20136 weeks. Dosages of ESAs are adjusted to maintain a target hemoglobin up to, but not exceeding, 10\u201312 g/dL. To support the increased erythropoiesis, nearly all patients with chronic kidney disease require oral or parenteral iron supplementation. Folate supplementation may also be necessary in some patients."
        },
        {
            "id": "InternalMed_Harrison_4489",
            "title": "InternalMed_Harrison",
            "content": "An overriding principle is to initiate treatment of mild to moderate anemia only when a specific diagnosis is made. Rarely, in the acute setting, anemia may be so severe that red cell transfusions are required before a specific diagnosis is available. Whether the anemia is of acute or gradual onset, the selection of the appropriate treatment is determined by the documented cause(s) of the anemia. Often, the cause of the anemia is multifactorial. For example, a patient with severe rheumatoid arthritis who has been taking anti-inflammatory drugs may have a hypoproliferative anemia associated with chronic inflammation as well as chronic blood loss associated with intermittent gastrointestinal bleeding. In every circumstance, it is important to evaluate the patient\u2019s iron status fully before and during the treatment of any anemia. Transfusion is discussed in Chap. 138e; iron therapy is discussed in Chap. 126; treatment of megaloblastic anemia is discussed in Chap. 128; treatment of other"
        },
        {
            "id": "First_Aid_Step1_460",
            "title": "First_Aid_Step1",
            "content": "Historically diagnosed with the Schilling test, a test that determines if the cause is dietary insufficiency vs malabsorption. Anemia 2\u00b0 to insufficient intake may take several years to develop due to liver\u2019s ability to store B12 (as opposed to folate deficiency). Nonhemolytic, normocytic anemias Anemia of chronic disease Inflammation (eg, \u008f IL-6) \u008e\u008f hepcidin (released by liver, binds ferroportin on intestinal mucosal cells and macrophages, thus inhibiting iron transport) \u008e\u0090 release of iron from macrophages and \u2022 iron absorption from gut. Associated with conditions such as chronic infections, neoplastic disorders, chronic kidney disease, and autoimmune diseases (eg, SLE, rheumatoid arthritis). \u0090 iron, \u0090 TIBC, \u008f ferritin. Normocytic, but can become microcytic. Treatment: address underlying cause of inflammation, judicious use of blood transfusion, consider erythropoiesisstimulating agents such as EPO (eg, in chronic kidney disease)."
        },
        {
            "id": "InternalMed_Harrison_4478",
            "title": "InternalMed_Harrison",
            "content": "failure. With diabetes mellitus or myeloma, the EPO deficiency may be more marked than would be predicted by the degree of renal insufficiency. In general, hypoproliferative anemias are characterized by normocytic, normochromic red cells, although microcytic, hypochromic cells may be observed with mild iron deficiency or long-standing chronic inflammatory disease. The key laboratory tests in distinguishing between the various forms of hypoproliferative anemia include the serum iron and iron-binding capacity, evaluation of renal and thyroid function, a marrow biopsy or aspirate to detect marrow damage or infiltrative disease, and serum ferritin to assess iron stores. An iron stain of the marrow will determine the pattern of iron distribution. Patients with the anemia of acute or chronic inflammation show a distinctive pattern of serum iron (low), TIBC (normal or low), percent transferrin saturation (low), and serum ferritin (normal or high). These changes in iron values are brought"
        },
        {
            "id": "InternalMed_Harrison_4444",
            "title": "InternalMed_Harrison",
            "content": "With acute hemolysis, the signs and symptoms depend on the mechanism that leads to red cell destruction. Intravascular hemolysis with release of free hemoglobin may be associated with acute back pain, free hemoglobin in the plasma and urine, and renal failure. Symptoms associated with more chronic or progressive anemia depend on the age of the patient and the adequacy of blood supply to critical organs. Symptoms associated with moderate anemia include fatigue, loss of stamina, breathlessness, and tachycardia (particularly with physical exertion). However, because of the intrinsic compensatory mechanisms that govern the O2\u2013hemoglobin dissociation curve, the gradual onset of anemia\u2014particularly in young patients\u2014may not be associated with signs or symptoms until the anemia is severe (hemoglobin <70\u201380 g/L [7\u20138 g/dL]). When anemia develops over a period of days or weeks, the total blood volume is normal to slightly increased, and changes in cardiac output and regional blood flow help"
        },
        {
            "id": "Pharmacology_Katzung_3688",
            "title": "Pharmacology_Katzung",
            "content": "Normally, an inverse relationship exists between the hematocrit or hemoglobin level and the serum erythropoietin level. Nonanemic individuals have serum erythropoietin levels of less than 20 IU/L. As the hematocrit and hemoglobin levels fall and anemia becomes more severe, the serum erythropoietin level rises exponentially. Patients with moderately severe anemia usually have erythropoietin levels in the 100\u2013500 IU/L range, and patients with severe anemia may have levels of thousands of IU/L. The most important exception to this inverse relationship is in the anemia of chronic renal failure. In patients with renal disease, erythropoietin levels are usually low because the kidneys cannot produce the growth factor. These are the patients most likely to respond to treatment with exogenous erythropoietin. In most primary bone marrow disorders (aplastic anemia, leukemias, myeloproliferative and myelodysplastic disorders, etc) and most nutritional and secondary anemias, endogenous"
        },
        {
            "id": "InternalMed_Harrison_4439",
            "title": "InternalMed_Harrison",
            "content": "FIguRE 77-2 Erythropoietin (EPO) levels in response to anemia. When the hemoglobin level falls to 120 g/L (12 g/dL), plasma EPO levels increase logarithmically. In the presence of chronic kidney Cardinal Manifestations and Presentation of Diseases disease or chronic inflammation, EPO levels are typically lower than expected for the degree of anemia. As individuals age, the level of EPO needed to sustain normal hemoglobin levels appears to increase."
        },
        {
            "id": "Physiology_Levy_3169",
            "title": "Physiology_Levy",
            "content": "production and secretion. Erythropoietin stimulates red blood cell formation by bone marrow. Decreased erythrocyte production contributes to the anemia that occurs in chronic kidney disease (CKD), a progressive loss in kidney function over a period of months or years."
        },
        {
            "id": "InternalMed_Harrison_8015",
            "title": "InternalMed_Harrison",
            "content": "Many patients with hypoproliferative anemias experience recovery of normal hemoglobin levels when the underlying disease is appropriately treated. For those in whom such reversals are not possible\u2014 such as patients with end-stage kidney disease, cancer, and chronic inflammatory diseases\u2014symptomatic anemia requires treatment. The two major forms of treatment are transfusions and EPO."
        },
        {
            "id": "InternalMed_Harrison_8000",
            "title": "InternalMed_Harrison",
            "content": "In addition to mild to moderate iron-deficiency anemia, the hypo-proliferative anemias can be divided into four categories: (1) chronic inflammation, (2) renal disease, (3) endocrine and nutritional deficiencies (hypometabolic states), and (4) marrow damage (Chap. 130). With chronic inflammation, renal disease, or hypometabolism, endogenous EPO production is inadequate for the degree of anemia observed. For the anemia of chronic inflammation, the erythroid marrow also responds inadequately to stimulation, due in part to defective iron reutilization. As a result of the lack of adequate EPO stimulation, an examination of the peripheral blood smear will disclose only an occasional polychromatophilic (\u201cshift\u201d) reticulocyte. In cases of iron deficiency or marrow damage, appropriate elevations in endogenous EPO levels are typically found, and shift reticulocytes will be present on the blood smear."
        },
        {
            "id": "InternalMed_Harrison_3573",
            "title": "InternalMed_Harrison",
            "content": "Renal Disease and Hyperkalemia Chronic kidney disease and end-stage kidney disease are very common causes of hyperkalemia, due to the associated deficit or absence of functioning nephrons. Hyperkalemia is more common in oliguric acute kidney injury; distal tubular flow rate and Na+ delivery are less limiting factors in nonoliguric patients. Hyperkalemia out of proportion to GFR can also be seen in the context of tubulointerstitial disease that affects the distal nephron, such as amyloidosis, sickle cell anemia, interstitial nephritis, and obstructive uropathy."
        },
        {
            "id": "Pathology_Robbins_2658",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net Disorders of red cells can result in anemia or, less commonly, polycythemia (an increase in red cells also known as erythrocytosis). Anemia is defined as a reduction in the oxygen-transporting capacity of blood, resulting from a decrease in the red cell mass to subnormal levels. Anemia can stem from bleeding, increased red cell destruction, or decreased red cell production. These mech anisms serve as one basis for classifying anemia (Table 12.1 ). In some entities overlap occurs, for example in thalassemia, wherebothreducedredcellproductionandearlydestruction contribute to anemia. With the exception of anemia caused by chronic renal failure or chronic inflammation (described Table 12.1 Classification of Anemia According to Underlying Mechanism Acute:traumaChronic:gastrointestinaltractlesions,gynecologicdisturbances MembraneabnormalitiesMembraneskeletonproteins:spherocytosis,elliptocytosisMembranelipids:abetalipoproteinemia"
        },
        {
            "id": "Obstentrics_Williams_7695",
            "title": "Obstentrics_Williams",
            "content": "In early pregnancy, anemia caused by acute blood loss is common with abortion, ectopic pregnancy, and hydatidiform mole. Postpartum, anemia commonly stems from obstetrical hemorrhage. Massive hemorrhage demands immediate treatment as described in Chapter 41 (p. 788). If a moderately anemic woman-defined by a hemoglobin value of approximately 7 g/dL-is hemodynamically stable, is able to ambulate without adverse symptoms, and is not septic, then blood transfusions are not indicated. Instead, oral iron therapy is given for at least 3 months (Kraft, 2005) . \u2022 Anemia Associated with Chronic Disease Various disorders, such as chronic renal insuiciency, cancer and chemotherapy, human immunodeficiency virus (HIV) infection, and chronic inflammation result in moderate and sometimes severe anemia, usually with slightly hypochromic and microcytic erythrocytes. It is the second most common form of anemia worldwide (Weiss, 2005)."
        },
        {
            "id": "InternalMed_Harrison_21660",
            "title": "InternalMed_Harrison",
            "content": "The anemia of CKD is associated with a number of adverse pathophysiologic consequences, including decreased tissue oxygen delivery and utilization, increased cardiac output, ventricular dilation, and ventricular hypertrophy. Clinical manifestations include fatigue and diminished exercise tolerance, angina, heart failure, decreased cognition and mental acuity, and impaired host defense against infection. In addition, anemia may play a role in growth restriction in children with CKD. Although many studies in CKD patients have found that anemia and resistance to exogenous erythropoietic-stimulating agents (ESA) are associated with a poor prognosis, the relative contribution to a poor outcome of the low hematocrit itself, versus inflammation as a cause of the anemia and ESA resistance, remains unclear."
        },
        {
            "id": "InternalMed_Harrison_21713",
            "title": "InternalMed_Harrison",
            "content": "Commonly accepted criteria for initiating patients on maintenance dialysis include the presence of uremic symptoms, the presence of hyperkalemia unresponsive to conservative measures, persistent extracellular volume expansion despite diuretic therapy, acidosis refractory to medical therapy, a bleeding diathesis, and a creatinine clearance or estimated glomerular filtration rate (GFR) below 10 mL/min per 1.73 m2 (see Chap. 335 for estimating equations). Timely referral to a nephrologist for advanced planning and creation of a dialysis access, education about ESRD treatment options, and management of the complications of advanced chronic kidney disease (CKD), including hypertension, anemia, acidosis, and secondary hyperparathyroidism, are advisable. Recent data have suggested that a sizable fraction of ESRD cases result following episodes of acute renal failure, particularly among persons with underlying CKD. Furthermore, there is no benefit to initiating dialysis preemptively at a GFR"
        },
        {
            "id": "Physiology_Levy_3168",
            "title": "Physiology_Levy",
            "content": "Finally, the kidneys are important endocrine organs that produce and secrete renin, calcitriol, and erythropoietin. Renin is not a hormone but an enzyme that activates the renin-angiotensin-aldosterone system, which helps regulate blood pressure and Na+ and K+ balance. Calcitriol, a metabolite of vitamin D3, is necessary for normal absorption of Ca++ by the gastrointestinal tract and for its deposition in bone (see ). In patients with renal disease the kidneys\u2019 ability to produce calcitriol is impaired and levels of this hormone are reduced. As a result, Ca++ absorption by the intestine is decreased, which over time contributes to the bone formation abnormalities seen in patients with chronic renal disease. Another consequence of many kidney diseases is a reduction in erythropoietin production and secretion. Erythropoietin stimulates red blood cell formation by bone marrow. Decreased erythrocyte production contributes to the anemia that occurs in chronic kidney disease (CKD), a"
        },
        {
            "id": "InternalMed_Harrison_4473",
            "title": "InternalMed_Harrison",
            "content": "DEFINITION AND CLASSIFICATION OF ANEMIA Initial Classification of Anemia The functional classification of anemia has three major categories. These are (1) marrow production defects (hypoproliferation), (2) red cell maturation defects (ineffective erythropoiesis), and (3) decreased red cell survival (blood loss/hemolysis). The classification is shown in Fig. 77-17. A hypoproliferative anemia is typically seen with a low reticulocyte production index together with little or no change in red cell morphology (a normocytic, normochromic anemia) (Chap. 126). Maturation disorders typically have a slight to moderately elevated reticulocyte production index that is accompanied by either macrocytic (Chap. 128) or microcytic (Chaps. 126, 127) red cell indices. Increased red blood cell destruction secondary to hemolysis results in an increase in the reticulocyte production index to at least three times normal (Chap. 129), provided sufficient iron is available. Hemorrhagic anemia does not"
        },
        {
            "id": "InternalMed_Harrison_21659",
            "title": "InternalMed_Harrison",
            "content": "HEMATOLOGIC ABNORMALITIES Anemia A normocytic, normochromic anemia is observed as early as stage 3 CKD and is almost universal by stage 4. The primary cause in patients with CKD is insufficient production of erythropoietin (EPO) by the diseased kidneys. Additional factors are reviewed in Table 335-3."
        },
        {
            "id": "Pathology_Robbins_2739",
            "title": "Pathology_Robbins",
            "content": "\u2022X-linkeddisordercausedbymutationsthatdestabilizeG6PD,makingredcellssusceptibletooxidantdamage Anemias of diminished erythropoiesis include those caused by an inadequate dietary supply of nutrients, particularly iron, folic acid, and vitamin B12. Other anemias of this type are associated with bone marrow failure (aplastic anemia), systemic inflammation (anemia of chronic inflammation), or bone marrow infiltration by tumor or inflammatory cells (myelophthisic anemia). In this section, some common examples of anemias of these types are discussed individually."
        },
        {
            "id": "Pathology_Robbins_2672",
            "title": "Pathology_Robbins",
            "content": "With chronic blood loss, iron stores are gradually depleted. Iron is essential for hemoglobin synthesis and erythropoiesis, and its deficiency leads to a chronic anemia of underproduction. Iron deficiency anemia can occur in other clinical settings as well; it is described later along with other forms of anemia caused by decreased red cell production."
        },
        {
            "id": "InternalMed_Harrison_21649",
            "title": "InternalMed_Harrison",
            "content": "Hypertension and Left Ventricular Hypertrophy Hypertension is one of the most common complications of CKD. It usually develops early during the course of CKD and is associated with adverse outcomes, including the development of ventricular hypertrophy and a more rapid loss of renal function. Many studies have shown a relationship between the level of blood pressure and the rate of progression of diabetic and nondiabetic kidney disease. Left ventricular hypertrophy and dilated cardiomyopathy are among the strongest risk factors for cardiovascular morbidity and mortality in patients with CKD and are thought to be related primarily, but not exclusively, to prolonged hypertension and ECFV overload. In addition, anemia and the placement of an arteriovenous fistula for hemodialysis can generate a high cardiac output state and consequent heart failure."
        },
        {
            "id": "InternalMed_Harrison_8287",
            "title": "InternalMed_Harrison",
            "content": "laboratory investigations and diagnosis The most consistent blood finding is anemia, which may range from mild to moderate to very severe. The anemia is usually normomacrocytic, with unremarkable red cell morphology. If the MCV is high, it is usually largely accounted for by reticulocytosis, which may be quite marked (up to 20%, or up to 400,000/\u03bcL). The anemia may become microcytic if the patient is allowed to become iron deficient as a result of chronic urinary blood loss through hemoglobinuria. Unconjugated bilirubin is mildly or moderately elevated; LDH is typically markedly elevated (values in the thousands are common); and haptoglobin is usually undetectable. All of these findings make the diagnosis of hemolytic anemia compelling. Hemoglobinuria may be overt in a random urine sample; if it is not, it may be helpful to obtain serial urine samples, because hemoglobinuria can vary dramatically from day to day and even from hour to hour. The bone marrow is usually cellular, with"
        },
        {
            "id": "InternalMed_Harrison_8206",
            "title": "InternalMed_Harrison",
            "content": "Compensated Hemolysis Versus Hemolytic Anemia Red cell destruction is a potent stimulus for erythropoiesis, which is mediated by erythropoietin (EPO) produced by the kidney. This mechanism is so effective that in many cases the increased output of red cells from the bone marrow can fully balance an increased destruction of red cells. In such cases, we say that hemolysis is compensated. The pathophysiology of compensated hemolysis is similar to what we have just described, except there is no anemia. This notion is important from the diagnostic point of view, because a patient with a hemolytic condition, even an inherited one, may present without anemia; and it is also important from the point of view of management, because compensated hemolysis may become \u201cdecompensated,\u201d i.e., anemia may suddenly appear, in certain circumstances, for instance in pregnancy, folate deficiency, or renal failure interfering with adequate EPO production. Another general feature of chronic HAs is seen when"
        },
        {
            "id": "Pharmacology_Katzung_3726",
            "title": "Pharmacology_Katzung",
            "content": "Albaramki J et al: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;(1):CD007857. Auerbach M, Al Talib K: Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528. Barzi A, Sekeres MA: Myelodysplastic syndromes: A practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37. Brittenham GM: Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146. Clark SF: Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol 2009;25:122. Darshan D, Fraer DM, Anderson GJ: Molecular basis of iron-loading disorders. Expert Rev Mol Med 2010;12:e36. Gertz MA: Current status of stem cell mobilization. Br J Haematol 2010;150:647. Kessans MR, Gatesman ML, Kockler DR: Plerixafor: A peripheral blood stem cell mobilizer. Pharmacotherapy 2010;30:485."
        },
        {
            "id": "Pathology_Robbins_2750",
            "title": "Pathology_Robbins",
            "content": "Persons often die with iron deficiency anemia, but virtually never of it. An important point is that in well-nourished persons, microcytic hypochromic anemia is not a disease but rather a symptom of some underlying disorder. Often referred to as the anemia of chronic disease, anemia associated with chronic inflammation is the most common form of anemia in hospitalized patients. It superficially resembles the anemia of iron deficiency but arises instead from the suppression of erythropoiesis by systemic inflammation. It occurs in a variety of disorders associated with sustained inflammation: \u2022 Chronic microbial infections, such as osteomyelitis, bacterial endocarditis, and lung abscess http://ebooksmedicine.net Chronic immune disorders, such as rheumatoid arthritis and regional enteritis Neoplasms, such as Hodgkin lymphoma and carcinomas of the lung and breast"
        },
        {
            "id": "Obstentrics_Williams_7697",
            "title": "Obstentrics_Williams",
            "content": "For treatment, adequate iron stores must be ensured. Recombinant eythropoietin has been used successfully to treat anemia stemming from chronic disease (Weiss, 2005). In pregnancies complicated by chronic renal insuiciency, recombinant erythropoietin is usually considered when the hematocrit approximates 20 percent (Cyganek, 2011; Ramin, 2006). One worrisome side efect of this agent is hypertension, which is already prevalent in women with renal disease. Red cell aplasia and antierythropoietin antibodies have also reported (Casadevall, 2002; McCoy, 2008). These anemias are characterized by blood and bone-marrow abnormalities from impaired DNA synthesis. This leads to large cells with arrested nuclear maturation, whereas the cytoplasm matures more normally. Worldwide, the prevalence of megaloblastic anemia during pregnancy varies considerably. It is rare in the United States."
        },
        {
            "id": "InternalMed_Harrison_3359",
            "title": "InternalMed_Harrison",
            "content": "Once GFR reduction has been established, the physician must decide if it represents acute or chronic renal injury. The clinical situation, history, and laboratory data often make this an easy distinction. However, the laboratory abnormalities characteristic of chronic renal failure, including anemia, hypocalcemia, and hyperphosphatemia, often are present as well in patients presenting with acute renal failure. Radiographic evidence of renal osteodystrophy (Chap. 335) can be seen only in chronic renal failure but is a very late finding, and these patients are usually undergoing dialysis. The urinalysis and renal ultrasound can facilitate distinguishing acute from chronic renal failure. An approach to the evaluation of azotemic patients is shown in Fig. 61-1. Patients with advanced chronic renal insufficiency often have some proteinuria, nonconcentrated urine (isosthenuria; isosmotic with plasma), and small kidneys on ultrasound, characterized by increased echogenicity and cortical"
        },
        {
            "id": "Pediatrics_Nelson_3466",
            "title": "Pediatrics_Nelson",
            "content": "Table 165-4 Classification of the Stages of Chronic Kidney Disease STAGE GFR (ml/min/ 1.73 m2)* DESCRIPTION >90 Minimal kidney damage 2 60\u201389 Kidney damage with mild reduction of GFR 3 30\u201359 Moderate reduction of GFR 4 15\u201329 Severe reduction of GFR 5 <15 (or dialysis) End-stage renal disease From National Kidney Foundation Kidney Disease Outcomes Quality Initiative. GFR, Glomerular filtration rate. *GFR ranges apply for children 2 years of age and older. 1. Poor growth Increased caloric intake, treat acidosis, treat renal osteodystrophy, recombinant GH 2. Anemia Erythropoietin, iron supplementation 3. Renal 1,25-Dihydroxyvitamin D osteodystrophy/ supplementation, calcium secondary supplementation, dietary phosphorous hyperparathyroidism restriction, phosphate binders 4. Cardiovascular 4a. Hypertension Antihypertensive medications 4b. Left ventricular Volume control hypertrophy 5."
        },
        {
            "id": "InternalMed_Harrison_8014",
            "title": "InternalMed_Harrison",
            "content": "Anemia in Liver Disease A mild hypoproliferative anemia may develop in patients with chronic liver disease from nearly any cause. The peripheral blood smear may show spur cells and stomatocytes from the accumulation of excess cholesterol in the membrane from a deficiency of lecithin-cholesterol acyltransferase. Red cell survival is shortened, and the production of EPO is inadequate to compensate. In alcoholic liver disease, nutritional deficiencies are common and complicate the management. Folate deficiency from inadequate intake, as well as iron deficiency from blood loss and inadequate intake, can alter the red cell indices."
        }
    ],
    "scores": [
        0.03548719966409271,
        0.033734408920477334,
        0.03315088487502281,
        0.031874731874731874,
        0.02929225488550951,
        0.02875776057081926,
        0.02870243048897162,
        0.02766364929724997,
        0.02625137323079877,
        0.025519233581980397,
        0.025116340912112754,
        0.024575783861755733,
        0.023818103692418872,
        0.023797807725390606,
        0.02262712694835265,
        0.022311656355830004,
        0.021879136052426362,
        0.021805963964211934,
        0.020626562711697397,
        0.019570321144437214,
        0.019419306184012067,
        0.018543956043956044,
        0.018513517728789845,
        0.018428197543752807,
        0.018199143692564743,
        0.017862838915470493,
        0.017681931016461983,
        0.01743750935488699,
        0.016866619618913198,
        0.01647058823529412,
        0.016230104023060535,
        0.016186638155550073
    ]
}